scholarly journals Visual Function Metrics in Early and Intermediate Dry Age-related Macular Degeneration for Use as Clinical Trial Endpoints

2018 ◽  
Vol 189 ◽  
pp. 127-138 ◽  
Author(s):  
Kimberly J. Cocce ◽  
Sandra S. Stinnett ◽  
Ulrich F.O. Luhmann ◽  
Lejla Vajzovic ◽  
Anupama Horne ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Macular Degeneration ◽  
Visual Function ◽  
Age Related Macular Degeneration ◽  
Clinical Trial Endpoints ◽  
Age Related ◽  
Trial Endpoints

scholarly journals Anatomic Clinical Trial Endpoints for Nonexudative Age-Related Macular Degeneration

Ophthalmology ◽  
2016 ◽  
Vol 123 (5) ◽  
pp. 1060-1079 ◽  
Author(s):  
Karen B. Schaal ◽  
Philip J. Rosenfeld ◽  
Giovanni Gregori ◽  
Zohar Yehoshua ◽  
William J. Feuer
Keyword(s):  
Clinical Trial ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Clinical Trial Endpoints ◽  
Age Related ◽  
Trial Endpoints

scholarly journals Clinical Perspectives and Trends: Microperimetry as a trial endpoint in retinal disease

2021 ◽  
Author(s):  
Yesa Yang ◽  
Hannah Dunbar
Keyword(s):  
Clinical Trial ◽  
Retinal Disease ◽  
Age Related Macular Degeneration ◽  
Gene Therapies ◽  
Age Related ◽  
Wide Range ◽  
Trial Endpoints ◽  
Visual Acuity Loss ◽  
Psychophysical Test ◽  
Trial Endpoint

Endpoint development trials are underway across the spectrum of retinal disease. New validated endpoints are urgently required for the assessment of emerging gene therapies and in preparation for the arrival of novel therapeutics targeting early stages of common sight-threatening conditions such as age-related macular degeneration. Visual function measures are likely to be key candidates in this search. Over the last two decades, microperimetry has been used extensively to characterize functional vision in a wide range of retinal conditions, detecting subtle defects in retinal sensitivity that precede visual acuity loss and tracking disease progression over relatively short periods. Given these appealing features, microperimetry has already been adopted as an endpoint in interventional studies, including multicenter trials, on a modest scale. A review of its use to date shows a concurrent lack of consensus in test strategy and a wealth of innovative disease and treatment-specific metrics which may show promise as clinical trial endpoints. There are practical issues to consider, but these have not held back its popularity and it remains a widely used psychophysical test in research. Endpoint development trials will undoubtedly be key in understanding the validity of microperimetry as a clinical trial endpoint, but existing signs are promising.

Sign in / Sign up

Export Citation Format

Share Document